Synfini, Inc. combines expert-curated AI with robotic automation to streamline molecular discovery, significantly reducing the time and cost associated with synthesizing and validating new drug candidates. By integrating physical and virtual chemistry, the platform enables pharmaceutical companies to efficiently translate computational drug concepts into validated candidates, aiming to generate over a thousand new drug candidates in the next decade.
Funding
$1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
The increasing number of drug targets and virtual drug hits identified through computational chemistry and generative AI has created a bottleneck in physical synthesis and testing. Traditional methods for synthesizing and validating new molecules are costly and time-consuming, hindering the development of new therapeutics.
Solution
Synfini offers an AI-powered drug discovery platform that integrates physical and virtual chemistry with robotic automation to accelerate the synthesis and validation of new drug candidates. The platform combines chemist-first AI and chemistry robotic automation to generate robust data for validating new drug designs rapidly and cost-effectively. By uniting the virtual and physical aspects of drug discovery, Synfini helps medicinal chemists speed up lead optimization, improve predictive accuracy, and explore a wider range of chemical possibilities. This approach aims to streamline the translation of targets, hits, and virtual drug concepts into validated candidates.
Target Audience
Synfini's primary customers are pharmaceutical companies and research institutions seeking to accelerate their drug discovery process and reduce the associated costs.
Features
- Chemist-first AI algorithms for molecular design and optimization
- Robotic automation for high-throughput synthesis and testing
- Integration of physical and virtual chemistry workflows
- Rapid generation of robust data for drug candidate validation
- Streamlined lead optimization process
- Improved predictive accuracy in drug discovery